150 related articles for article (PubMed ID: 18288943)
1. Targeting P-glycoprotein for effective oral anti-cancer chemotherapeutics.
Bebawy M; Sze DM
Curr Cancer Drug Targets; 2008 Feb; 8(1):47-52. PubMed ID: 18288943
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.
Binkhathlan Z; Lavasanifar A
Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
4. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
Waghray D; Zhang Q
J Med Chem; 2018 Jun; 61(12):5108-5121. PubMed ID: 29251920
[TBL] [Abstract][Full Text] [Related]
5. β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer.
Bar-Zeev M; Kelmansky D; Assaraf YG; Livney YD
Eur J Pharm Biopharm; 2018 Dec; 133():240-249. PubMed ID: 30367935
[TBL] [Abstract][Full Text] [Related]
6. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?
Callaghan R; Luk F; Bebawy M
Drug Metab Dispos; 2014 Apr; 42(4):623-31. PubMed ID: 24492893
[TBL] [Abstract][Full Text] [Related]
8. Pyramidatine (Z88) Sensitizes Vincristine-Resistant Human Oral Cancer (KB/VCR) Cells to Chemotherapeutic Agents by Inhibition of P-glycoprotein.
Liu Z; Zhu H; Qu S; Tang L; Cao L; Yu W; Yang X; Jiang S; Zhu D; Tan C; Yu L
Anticancer Agents Med Chem; 2018; 18(2):286-294. PubMed ID: 28782465
[TBL] [Abstract][Full Text] [Related]
9. Effect of endogenous multidrug resistance 1 and P-glycoprotein expression on anticancer drug resistance in colon cancer cell lines.
Washio I; Nakanishi T; Ishiguro N; Bister B; Tamai I
Biopharm Drug Dispos; 2019 Jan; 40(1):32-43. PubMed ID: 30556139
[TBL] [Abstract][Full Text] [Related]
10. Modulation of oral bioavailability of anticancer drugs: from mouse to man.
Schellens JH; Malingré MM; Kruijtzer CM; Bardelmeijer HA; van Tellingen O; Schinkel AH; Beijnen JH
Eur J Pharm Sci; 2000 Dec; 12(2):103-10. PubMed ID: 11102737
[TBL] [Abstract][Full Text] [Related]
11. Emerging advances in P-glycoprotein inhibitory nanomaterials for drug delivery.
Kou L; Sun R; Bhutia YD; Yao Q; Chen R
Expert Opin Drug Deliv; 2018 Sep; 15(9):869-879. PubMed ID: 30169976
[TBL] [Abstract][Full Text] [Related]
12. Cancer cell permeability-glycoprotein as a target of MDR reverters: possible role of novel dihydropyridine derivatives.
Fusi F; Saponara S; Valoti M; Dragoni S; D'Elia P; Sgaragli T; Alderighi D; Kawase M; Shah A; Motohashi N; Sgaragli G
Curr Drug Targets; 2006 Aug; 7(8):949-59. PubMed ID: 16918323
[TBL] [Abstract][Full Text] [Related]
13. Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy.
Saneja A; Dubey RD; Alam N; Khare V; Gupta PN
Curr Cancer Drug Targets; 2014; 14(5):419-33. PubMed ID: 24720364
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein inhibition: the past, the present and the future.
Darby RA; Callaghan R; McMahon RM
Curr Drug Metab; 2011 Oct; 12(8):722-31. PubMed ID: 21434857
[TBL] [Abstract][Full Text] [Related]
15. Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment.
Stanković T; Dinić J; Podolski-Renić A; Musso L; Burić SS; Dallavalle S; Pešić M
Curr Med Chem; 2019; 26(33):6074-6106. PubMed ID: 29874992
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein mediated multidrug resistance and its implications for pathology.
Trambas CM; Muller HK; Woods GM
Pathology; 1997 May; 29(2):122-30. PubMed ID: 9213329
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of multidrug resistance.
Sonneveld P; Wiemer E
Curr Opin Oncol; 1997 Nov; 9(6):543-8. PubMed ID: 9370075
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of p-glycoprotein--lead identification and optimisation.
Pleban K; Ecker GF
Mini Rev Med Chem; 2005 Feb; 5(2):153-63. PubMed ID: 15720285
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
